Lee JS, Ruppin E. - A variety of neoantigen-, checkpoint-, and immune response–related variables were evaluated in order to assess the key variables that correctly prognosticate the response to therapy to inhibit programmed cell death 1 and its ligand (anti–PD-1/PD-L1) in various cancer types. Bt performing this analysis of multiomics data from the Cancer Genome Atlas cohort and objective response rates to therapy data across 21 cancer types, researchers found the highest predictive value in estimated CD8+ T-cell abundance, followed by tumor mutational burden and the fraction of samples with high programmed cell death 1 gene expression. Findings suggest the requirement of immune, neoantigen, and checkpoint target variables in combination to accurately predict the response to anti–PD-1/PD-L1 therapy across multiple cancers.